GDF-15 levels in progressors and nonprogressors in albuminuria (case and control subjects) for patients with T2DM and nondiabetic patients with HT. A:

Slides:

Advertisements

Similar presentations

לדיובן הגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים ונורמוטנסיבים) עם מיקרואלבומינוריה לדיובן הגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים.

Advertisements

Renal Structure in Normoalbuminuric and Albuminuric Patients With Type 2 Diabetes and Impaired Renal Function Featured Article: Elif I. Ekinci, P.H.D.,

Continued Smoking Exacerbates but Cessation Ameliorates Progression of Early Type 2 Diabetic Nephropathy Kantima Phisitkul, MD, Khaled Hegazy, MD, Temduang.

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure Mikhail Kosiborod, Ingrid Gause-Nilsson, John Xu,

Panelists. Type 2 Diabetes, Renal Impairment, and CHD: Reducing 2 Vascular Risks With 1 Stone.

A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.

Glycemic thresholds for subjective symptomatic awareness of hypoglycemia and for the onset of cognitive dysfunction in young and elderly nondiabetic males.

Baseline Characteristics

Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.

(A through C) Mean eGFR during follow-up according to treatment assignment in patients with normoalbuminuria (A), microalbuminuria (B), and macroalbuminuria.

Relationships between annual antibiotic purchase rates and progression of microalbuminuria in patients with type 1 diabetes. Relationships between annual.

A: Kaplan-Meier curves depicting the cumulative probability of CVE in patients with low (

Incidence rates and HRs for total cardiovascular events and stroke stratified by the TCF7L2-rs polymorphism and the dietary intervention group after.

The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.

Relationship between selected metabolic parameters and the primary composite end point. Relationship between selected metabolic parameters and the primary.

Age-adjusted OR (A) and multivariate-adjusted OR (B) and 95% CI for the presence of retinopathy and albuminuria by quintiles of WBC count in 3,776 patients.

Study protocol. Study protocol. Fourteen patients had research renal biopsies, and 17 patients with macroalbuminuria had renal biopsies for clinical reasons.

Mean mesangial area (micron2) across normal controls (normal C), patients with type 2 diabetes and normoalbuminuria (normo), patients with type 2 diabetes.

The incidence of insulin-treated type 1 diabetes in the first 35 years of life. The incidence of insulin-treated type 1 diabetes in the first 35 years.

Prevalence of clinically significant microvascular (green) and clinically significant macrovascular (yellow) disease alone and combined microvascular and.

Prevalence of high SAT or high VAT by BMI category in women (A) and men (B) and by waist circumference category in women (C) and men (D). Prevalence of.

FMD and PWV of patients with diabetes with (T2DM-SCT) or without (T2DM) SCT and of healthy individuals with (SCT) or without (CONT) SCT. FMD measured at.

Left columns: Plasma glucose and serum insulin concentrations, circulating TF-PCA, and FVIIa activity before and during 24 h of selective hyperglycemia.

Forefoot peak plantar pressure in diabetic patients without and with mild, moderate, and severe peripheral neuropathy. *Severe and moderate neuropathy.

The effect of sulfonylurea (glibenclamide = glyburide) and metformin therapy on the plasma HbA1c concentration in newly diagnosed T2DM subjects in UKPDS.

Expression of mRNA erythropoietin in the human retina.

Showing significant positive correlation of circulating plasma DPP4 levels with total intra-abdominal adipose tissue volume in patients with T2DM (A) and.

The effect of PAD and infection on outcome of cast treatment

Kaplan-Meier estimation of diabetes-related survival curves in patients grouped according to increased 24-h proteinuria (A), the presence of preexisting.

Mean fasting C-peptide levels (for all subjects [A]) and mean peak C-peptide levels (all subjects [B], adolescents [C], and adults [D])after mixed-meal.

Two-year changes in albumin-to-creatinine ratio across microalbuminuria at baseline. Two-year changes in albumin-to-creatinine ratio across microalbuminuria.

Effect of 4 weeks of an intensive exercise program on vaspin serum concentrations in normal glucose tolerant (NGT) individuals and patients with IGT or.

The prevalence of type 2 diabetes for R1420H carriers and noncarriers in relation to BMI. Diabetes prevalence is shown in individuals stratified by their.

Baseline and follow-up values for HbA1c, WBISI, IGI, and ODI in NGT subjects divided according to development of IGT at follow-up (progressors [dark green.

Baseline predictors of acute complication of diabetes among immigrants with language barriers (N = 87,707). *Adjustment for all variables listed, as well.

Baseline predictors for risk of cardiovascular events or all-cause mortality among immigrants with language barriers (N = 87,707). *Adjustment for all.

Average percent change in serum leptin and soluble leptin receptor (sOB-R) levels in response to rhLeptin administration at a low dose (0.01 mg/kg) (n.

Forest plot and pooled estimates of the effect of NAFLD on the risk of incident diabetes in 16 eligible studies, stratified by length of follow-up (FU)

Relationship between week 24 A1C and week 24 BeAM in the exploratory analysis (A), the main analysis (only patients with A1C >7.0% at week 24 were included.

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

Effect of empagliflozin on efficacy parameters at week 18.

A total of 173 individuals were positive for GADA, and 16 of these were positive for a second antibody (11 were IA-2A positive, and 6 were ZnT8A positive).

Kaplan-Meier survival curve for CVD mortality among physically active and inactive type 2 diabetic patients stratified by baseline hs-CRP levels. Kaplan-Meier.

Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.

Glycemic control and body weight over 52 weeks.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

Pooled analysis of association between (nonexclusive) breast-feeding and childhood-onset type 1 diabetes in studies investigating ∼2 weeks (nonexclusive)

Percent binding of cross-reactive antibodies from cross-over studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.

RBP4 and glucose metabolism.

Progression to micro- or macroalbuminuria.

Box-and-whisker plots of SMAP assessed by AUC in diabetic patients with normoalbuminuria and albuminuria, treated with or without aspirin. Box-and-whisker.

One-year cumulative incidence rates of adverse clinical outcomes in 9,428 outpatients with CHF stratified by diabetes status at baseline. One-year cumulative.

A: Typical course of a normal sympathetic vasomotor response as recorded by continuous wave Doppler sonography. A: Typical course of a normal sympathetic.

Plots of average estimated and measured GFR vs

New dialysis starts in the United States by year in patients with and without diagnosis of diabetes. New dialysis starts in the United States by year in.

Incidences of transitions between glycemic states by 25-OHD level.

A1C at baseline, 16 weeks, and 32 weeks according to study group in all participants (A), adult participants (B), and adolescent participants (C) who returned.

The prevalence of cerebral infarction in the subjects with zero to seven proatherothrombotic alleles. The prevalence of cerebral infarction in the subjects.

Kaplan-Meier survival (renal event-free) curves during follow-up by tertiles of plasma copeptin. Kaplan-Meier survival (renal event-free) curves during.

RR (with 95% CI) of total mortality (multivariate-adjusted) by duration of smoking cessation among diabetic women. RR (with 95% CI) of total mortality.

Complex association between Hb level and GFR, sex, and AER

Upper panel: For performance of the 10-g monofilament test, the device is placed perpendicular to the skin, with pressure applied until the monofilament.

Changes in urinary albumin excretion rate in relation to baseline (top), cross-sectional values of GFR (middle), and MABP (bottom) during treatment with.

WM volume did not show the expected increase in volume with age in children with type 1 diabetes (●), in contrast with HC subjects (▲) who showed the (expected)

Change in first-phase insulin response (A) and pancreas triglyceride content (B) in responders and nonresponders at baseline (hatched bars), after VLCD.

Four–time point diurnal profiles of plasma glucose concentrations (A) and AUCs (B) over quintiles of HbA1c. ○, AUC1; •, AUC2; ▴, AUC2 − AUC1 (differences.

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Adjusted HRs for death from any cause and death from specific causes among patients with type 1 diabetes. Adjusted HRs for death from any cause and death.

Few patients with youth-onset type 2 diabetes are available to participate in clinical trials. Few patients with youth-onset type 2 diabetes are available.

Insulin secretion (hyperglycemic clamp) (A), insulin sensitivity (hyperinsulinemic-euglycemic clamp) (B), and glucose disposition index (GDI) (C) in adolescents.

Presentation transcript:

GDF-15 levels in progressors and nonprogressors in albuminuria (case and control subjects) for patients with T2DM and nondiabetic patients with HT. A: GDF-15 levels (pg/mL) (mean ± SE) in progressors and nonprogressors in albuminuria for T2DM and HT. B: GDF-15 levels (pg/mL) (mean ± SE) in progressors and nonprogressors in albuminuria for T2DM and HT stratified for baseline albuminuria (normoalbuminuria [Normo] or microalbuminuria [Micro]); *P < 0.05, **P < 0.001. GDF-15 levels in progressors and nonprogressors in albuminuria (case and control subjects) for patients with T2DM and nondiabetic patients with HT. A: GDF-15 levels (pg/mL) (mean ± SE) in progressors and nonprogressors in albuminuria for T2DM and HT. B: GDF-15 levels (pg/mL) (mean ± SE) in progressors and nonprogressors in albuminuria for T2DM and HT stratified for baseline albuminuria (normoalbuminuria [Normo] or microalbuminuria [Micro]); *P < 0.05, **P < 0.001. Macro, macroalbuminuria. Merel E. Hellemons et al. Dia Care 2012;35:2340-2346 ©2012 by American Diabetes Association